Case 1:14-cv-01171-GMS Document 259 Filed 09/15/16 Page 1 of 170 PageID #: 5532
`Case 1:14-cv-01171-GMS Document 259 Filed 09/15/16 Page 1 of 170 PageID #: 5532
`
`IN THE UNITED STATES DISTRICT COURT
`
`FOR THE DISTRICT OF DELAWARE
`
`IN RE COPAXONE 40 MG CONSOLIDATED
`
`CASES
`
`CA. No. 14-1171-GMS
`
`(CONSOLIDATED)
`
`vvvvvv
`
`|PROPOSED| JOINT PRETRIAL ORDER
`
`REDACTED — PUBLIC VERSION
`
`

`

`Case 1:14-cv-01171-GMS Document 259 Filed 09/15/16 Page 2 of 170 PageID #: 5533
`
`Richard D. Kirk (No. 922)
`Stephen B. Brauerman (No. 4952)
`Sara E. Bussiere (No. 5725)
`BAYARD, P.A.
`222 Delaware Avenue, Suite 900
`Wilmington, DE 19801
`(302) 655-5000
`rkirk@bayardlaw.com
`sbrauerman@bayardlaw.com
`sbussiere@bayardlaw.com
`
`
`John W. Shaw (No. 3362)
`Karen E. Keller (No. 4489)
`David M. Fry (No. 5486)
`SHAW KELLER LLP
`300 Delaware Avenue, Suite 1120
`Wilmington, DE 19801
`(302) 298-0700
`jshaw@shawkeller.com
`kkeller@shawkeller.com
`dfry@shawkeller.com
`
`David M. Hashmall
`Elizabeth J. Holland
`GOODWIN PROCTER LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018
`(212) 813-8800
`
`Paul F. Ware
`Daryl L. Wiesen
`John T. Bennett
`Nicholas K. Mitrokostas
`GOODWIN PROCTER LLP
`100 Northern Avenue
`Boston, MA 02110
`(617) 570-1000
`
`William G. James
`GOODWIN PROCTER LLP
`901 New York Avenue, NW
`Washington, DC 20001
`(202) 346-4000
`
`Attorneys for Plaintiffs
`
`
`
`
`
`
`
`

`

`Case 1:14-cv-01171-GMS Document 259 Filed 09/15/16 Page 3 of 170 PageID #: 5534
`
`Richard L. Renck (No. 3893)
`DUANE MORRIS LLP
`222 Delaware Avenue, Suite 1600
`Wilmington, DE 19801
`(302) 657-4900
`
`Anthony J. Fitzpatrick
`Vincent L. Capuano
`Christopher S. Kroon
`Carolyn A. Alenci
`DUANE MORRIS LLP
`100 High Street, Suite 2400
`Boston, MA 02110
`(857) 488-4200
`
`Attorneys for Amneal Pharmaceuticals LLC
`
`
`
`
`Frederick L. Cottrell, III (No. 2555)
`Arun Mohan (No. 6110)
`RICHARDS, LAYTON & FINGER, P.C.
`One Rodney Square
`920 North King Street
`Wilmington, DE 19801
`(302) 651-7700
`cottrell@rlf.com
`mohan@rlf.com
`
`Shannon M. Bloodworth
`PERKINS COIE LLP
`700 13th Street, NW
`Washington, DC 20005
`(202) 654-6204
`
`Attorneys for Mylan Inc., Mylan
`Pharmaceuticals Inc. and Natco Pharma
`Ltd.
`
`
`
`
`
`
`
`
`
`John C. Phillips, Jr. (No. 110)
`David A. Bilson (No. 4986)
`PHILLIPS, GOLDMAN, MCLAUGHLIN
` & HALL, P.A.
`1200 North Broom Street
`Wilmington, DE 19806
`jcp@pgmhlaw.com
`dab@ pgmhlaw.com
`
`Constance S. Huttner
`Beshoy M. Sharoupim
`BUDD LARNER, P.C.
`150 John F. Kennedy Parkway
`Short Hills, NJ 07078
`(973) 315-4430
`
`Attorneys for DRL Defendants
`
`
`
`
`Dominick T. Gattuso (No. 3630)
`PROCTOR HEYMAN ENERIO LLP
`300 Delaware Avenue, Suite 200
`Wilmington, DE 19801
`(308) 472-7300
`dgattuso@proctorheyman.com
`
`William A. Rakoczy
`Deanne M. Mazzochi
`Rachel Pernic Waldron
`RAKOCZY MOLINO MAZZOCHI SIWIK LLP
`6 West Hubbard Street, Suite 500
`Chicago, IL 60654
`(312) 222-7543
`wrakoczy@rmmslegal.com
`dmazzochi@rmmslegal.com
`rwaldron@rmmslegal.com
`
`Attorneys for Defendants Sandoz Inc.
`and Momenta Pharmaceuticals, Inc.
`
`
`
`
`
`
`
`

`

`Case 1:14-cv-01171-GMS Document 259 Filed 09/15/16 Page 4 of 170 PageID #: 5535
`
`
`Neal C. Belgam (No. 2721)
`Eve H. Ormerod (No. 5369)
`SMITH, KATZENSTEIN & JENKINS LLP
`1000 West Street, Suite 1501
`P.O. Box 410
`Wilmington, DE 19899 (courier 19801)
`(302) 652-8400
`nbelgam@skjlaw.com
`eormerod@skjlaw.com
`
`E. Anthony Figg
`Sharon L. Davis
`R. Elizabeth Brenner-Leifer
`Seth E. Cockrum
`Jennifer Nock
`ROTHWELL, FIGG, ERNST &
`MANBECK, P.C.
`607 14th Street, NW, Suite 800
`Washington, DC 20005
`(202) 783-6040
`
`Attorneys for Synthon Pharmaceuticals Inc.,
`Synthon B.V, Synthon s.r.o., and Pfizer, Inc.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`

`

`Case 1:14-cv-01171-GMS Document 259 Filed 09/15/16 Page 5 of 170 PageID #: 5536
`
`
`
`
`This matter having come before the Court at a pretrial conference held pursuant to Fed.
`
`R. Civ. P. (“Rule”) 16, and Shaw Keller LLP, 300 Delaware Avenue, Suite 1120, Wilmington,
`
`DE 19801, Bayard, P.A., 222 Delaware Avenue, Suite 900, Wilmington, DE 19801, and
`
`Goodwin Procter LLP, 620 Eighth Avenue, New York, NY 10018, 100 Northern Avenue,
`
`Boston, MA 02210, and 901 New York Avenue, NW, Washington, DC 20001, having appeared
`
`as counsel for Plaintiffs Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries Ltd.,
`
`Teva Neuroscience, Inc. and Yeda Research and Development Co., Ltd. (collectively “Plaintiffs”
`
`or “Teva”); and Phillips, Goldman, McLaughlin & Hall, P.A., 1200 North Broom Street,
`
`Wilmington, DE 19806, and Budd Larner, P.C., 150 John F. Kennedy Parkway, Short Hills, NJ
`
`07078 having appeared as counsel for Defendant Doctor Reddy’s Laboratories, Ltd. (“DRL
`
`Ltd.”) and Doctor Reddy’s Laboratories, Inc. (“DRL Inc.”) (collectively “DRL”); and Richards,
`
`Layton & Finger, P.C., One Rodney Square, 920 North King Street, Wilmington, DE 19801, and
`
`Perkins Coie LLP, 700 13th Street, NW, Washington, DC 20005 having appeared as counsel for
`
`Defendant Mylan Pharmaceuticals Inc. and Mylan Inc. (collectively “Mylan”); and Proctor
`
`Heyman Enerio LLP, 300 Delaware Avenue, Suite 200, Wilmington, DE 19801, and Rakoczy
`
`Molino Mazzochi Siwik LLP, 6 West Hubbard Street, Suite 500, Chicago, IL 60654 having
`
`appeared as counsel for Defendant Sandoz, Inc. and Momenta Pharmaceuticals, Inc. (collectively
`
`“Sandoz”); and Smith, Katzenstein & Jenkins LLP, 1000 West Street, Suite 1501, Wilmington,
`
`DE 19899, and Rothwell, Figg, Ernst & Manbeck, P.C., 607 14th Street, NW, Suite 800,
`
`Washington, DC 20005 having appeared as counsel for Defendant Synthon Pharmaceuticals Inc.,
`
`Synthon B.V., Synthon s.r.o., and Pfizer Inc. (collectively “Synthon”); and Duane Morris LLP,
`
`222 Delaware Avenue, Suite 1600, Wilmington, DE 19801 having appeared as counsel for
`
`Defendant Amneal Pharmaceuticals LLC (“Amneal LLC”) and Amneal Pharmaceuticals
`
`
`
`1
`
`

`

`Case 1:14-cv-01171-GMS Document 259 Filed 09/15/16 Page 6 of 170 PageID #: 5537
`
`Company GmbH (“Amneal GmbH”) (collectively “Amneal”) (Defendants DRL, Mylan, Sandoz,
`
`Synthon and Amneal collectively referred to herein as “Defendants”), the following actions were
`
`taken.
`
`1.
`
`This is a consolidated civil action for patent infringement of U.S. Patent Nos. 8,232,250
`
`(“the ’250 patent”), 8,399,413 (“the ’413 patent”), 8,969,302 (“the ’302 patent), and 9,155,776
`
`(“the ’776 patent”) (collectively, “patents-in-suit”), arising under the patent laws and the Hatch-
`
`Waxman Act. See 35 U.S.C. §§ 1 et seq.; 21 U.S.C. § 355. The jurisdiction of the Court is
`
`invoked under 28 U.S.C. §§ 1331, 1338(a), 2201, and 2202. Plaintiffs state that venue is
`
`invoked under 28 U.S.C. §§ 1391 and 1400(b). Defendants do not contest jurisdiction or venue
`
`solely for the limited purpose of this action.
`
`2.
`
`The following stipulations and statements were submitted and are attached to and made a
`
`part of this Order:
`
`a)
`
`A comprehensive statement of all uncontested facts, which will become a part of
`
`the evidentiary record in this case (see Schedule A as well as Defendants’ Schedule A-2 to
`
`which Plaintiffs have not agreed).
`
`b)
`
`An agreed upon statement of the contested issues of fact and law (see Schedule
`
`B-1), statements by each party of the contested issues of fact and law (see Schedule B-2
`
`(Plaintiffs’ Statement of Contested Issues) and Schedule B-3 (Defendants’ Statement of
`
`Contested Issues)). If the Court determines that any issue identified in a party’s Statement of
`
`Contested Issues of Fact and Law as an issue of fact is more properly considered an issue of law,
`
`it shall be so considered. Similarly, if the Court determines that any issue identified in a party’s
`
`Statement of Contested Issues of Fact and Law as an issue of law is more properly considered an
`
`issue of fact, it shall be so considered.
`
`2
`
`
`
`

`

`Case 1:14-cv-01171-GMS Document 259 Filed 09/15/16 Page 7 of 170 PageID #: 5538
`
`c)
`
`Except for impeachment exhibits, schedules of all exhibits, including documents,
`
`summaries, charts and other items, expected to be offered into evidence (see Schedule C-1 (Joint
`
`Exhibit List), Schedule C-2 (Plaintiffs’ Exhibit List) and Schedule C-3 (Defendants’ Exhibit
`
`List)).
`
`(1)
`
`Subject to the remaining provisions of this Order, no Party may offer an
`
`exhibit not present on any party’s exhibit list absent good cause shown. Each party may use
`
`exhibits from the other party’s exhibit list, even if not separately listed on its own exhibit list.
`
`Any exhibit, once admitted at trial, may be used equally by each Party for any proper purpose in
`
`accordance with the Federal Rules of Evidence. The listing of a document on a Party’s list is not
`
`an admission that such document is relevant or admissible when offered by the opposing Party
`
`for the purpose that the opposing Party wishes to admit the document.
`
`(2)
`
`Each Party may use exhibits not set forth in its exhibit list, or any
`
`deposition or portion thereof, for purposes of impeachment. No party will remove a document
`
`once it has been added to the party’s exhibit list without agreement from the other party, unless it
`
`provides the other party the opportunity to add the document to its exhibit list.
`
`(3)
`
`The Parties agree that the demonstrative exhibits the Parties intend to use
`
`at trial do not need to be included on their respective lists of trial exhibits. Plaintiffs’
`
`demonstratives will be identified with PDX numbers 1-999. Defendants’ demonstratives will be
`
`identified with [Defendant/Defendants name]_DDX numbers, if specific to a particular
`
`defendant, otherwise Defendants’ demonstratives will be identified with DDX. All Defendants
`
`Demonstrative exhibits will begin with the number 1000. Blow-ups or highlights of exhibits or
`
`parts of exhibits or testimony need not be identified by separate PDX or DDX numbers.
`
`
`
`3
`
`

`

`Case 1:14-cv-01171-GMS Document 259 Filed 09/15/16 Page 8 of 170 PageID #: 5539
`
`(4)
`
`The parties shall identify for each witness they call the trial exhibits that
`
`they expect to use in direct examination by 7:00 p.m. two calendar days before the examination
`
`is expected to take place. Objections to trial exhibits shall be made by 6:00 p.m. the calendar
`
`day before the examination is expected to take place. The parties shall then meet and confer in
`
`an attempt to resolve any objections to the trial exhibits that are expected to be used during the
`
`direct examination no later than 9 p.m. the calendar day before the examination is expected to
`
`take place. If good faith efforts to resolve the objections fail, the party objecting to the exhibits
`
`shall bring its objections to the Court’s attention at the beginning of the trial day or as otherwise
`
`directed by the Court.
`
`(5)
`
`The parties agree that there is no requirement to disclose exhibits to be
`
`used for cross-examination prior to cross-examination. The cross-examining party will make
`
`reasonable efforts to provide the opposing party with the materials to be used during cross-
`
`examination at the beginning of the cross-examination.
`
`(6)
`
`The parties have agreed to the following procedure for the exchange of
`
`demonstrative exhibits to be used with witnesses on direct examination. For the direct
`
`examination of each witness, the party calling the witness shall provide the other party with final
`
`copies (subject only to addressing evidentiary objections and rulings or font/layout/formatting or
`
`typographical error corrections) of all demonstrative exhibits to be used in the direct examination
`
`of that witness by 7:00 p.m. the calendar day prior to the witness examination is expected to take
`
`place. With regard to the exchange of demonstrative exhibits, the party calling the witness must
`
`provide color PDF files or color copies (on 8½” x 11” paper or larger) of all demonstrative
`
`exhibits, and to the extent applicable, any demonstrative movies (e.g., .mpeg, .wmv, .vob files in
`
`native format) to be used with each witness on direct examination. The notice provisions of this
`
`
`
`4
`
`

`

`Case 1:14-cv-01171-GMS Document 259 Filed 09/15/16 Page 9 of 170 PageID #: 5540
`
`paragraph shall not apply to demonstrative exhibits created in the courtroom during testimony at
`
`trial or the enlargement, simple highlighting, ballooning, or excerption of trial exhibits or
`
`testimony. The parties shall then meet and confer no later than 9 p.m. the calendar day before
`
`the examination is expected to take place in an attempt to resolve any objections to any
`
`demonstrative exhibit. If good faith efforts to resolve the objections fail, the party objecting to
`
`the demonstrative exhibits shall bring its objections to the Court’s attention at the beginning of
`
`the trial day or as otherwise directed by the Court. Demonstrative exhibits used solely for the
`
`cross-examination of a witness need not be disclosed in advance of the cross-examination.
`
`(7)
`
`Any exhibit identified on a Party’s exhibit list and not objected to is
`
`deemed to be admissible and may be offered into evidence by the Party through an appropriate
`
`sponsoring witness, except that nothing herein shall be construed as a stipulation or admission
`
`that the document is entitled to any weight in deciding the merits of this case.
`
`(8)
`
`The Parties stipulate to the authenticity of all exhibits, except where
`
`specifically indicated with specific reasons for the objection noted. Any objection to a
`
`document’s authenticity must be made in this Pretrial Order.
`
`(9)
`
`Legible copies of United States patents and the contents of the Patent and
`
`Trademark Office file histories may be offered and received in evidence in lieu of certified
`
`copies thereof, subject to all other objections that might be made to the admissibility of certified
`
`copies.
`
`d)
`
`Lists of names and addresses of the potential witnesses to be called by each party,
`
`with a statement of any objections to calling, or to the qualifications of, any witness identified on
`
`the list (see Schedule D-1 (Plaintiffs’ Witness List) and Schedule D-2 (Defendants’ Witness
`
`List)).
`
`
`
`5
`
`

`

`Case 1:14-cv-01171-GMS Document 259 Filed 09/15/16 Page 10 of 170 PageID #: 5541
`
`(1)
`
`Each side’s list of deposition designations is incorporated by reference
`
`into its list of witnesses that it intends to call at trial, except that a Party may not call a witness
`
`for live testimony if that witness appears only on the list of deposition designations and not on
`
`the list of witnesses.
`
`(2)
`
`Any witness not listed in the schedules D-1 and D-2 referenced above will
`
`be precluded from testifying absent good cause shown, except that each Party reserves the right
`
`to call such rebuttal witnesses (who are not presently identifiable) as may be necessary, on
`
`reasonable notice to the opposing Party consistent with the provisions of this Order on
`
`identification of witnesses under D-5 and consistent with the obligations of Rule 26 of the
`
`Federal Rules of Civil Procedure.
`
`(3)
`
`The Parties’ lists of witnesses shall indicate (1) which witnesses will be
`
`called in the absence of reasonable notice to opposing counsel to the contrary and (2) which
`
`witnesses may be called as a possibility only.
`
`(4)
`
`The Parties further reserve the right to call one or more additional
`
`witnesses whose testimony is necessary to establish foundation, authenticity or admissibility of
`
`any trial exhibit, if the foundation, authenticity or admissibility of the exhibit is challenged by an
`
`opposing Party.
`
`(5)
`
`The Parties will identify the witnesses expected to testify by 7:00 p.m. two
`
`calendar days before the direct examination is to take place in the order that it intends to call
`
`those witnesses at trial. Further, each party shall identify whether each witness will be called live
`
`or by deposition. For example, for a witness expected to be called on Wednesday, the witness
`
`will be identified by 7:00 p.m. on Monday.
`
`
`
`6
`
`

`

`Case 1:14-cv-01171-GMS Document 259 Filed 09/15/16 Page 11 of 170 PageID #: 5542
`
`(6)
`
`Each party will give notice at 8:00 p.m. two calendar days before it
`
`reasonably expects to complete the presentation of evidence in its case in chief.
`
`e)
`
`Statements setting forth the qualifications of each expert witness and the subject
`
`matter of each expert’s testimony (see Schedule E-1 (Plaintiffs’ Expert Witnesses’
`
`Qualifications) and Schedule E-2 (Defendants’ Expert Witnesses’ Qualifications)).
`
`f)
`
`Lists of all depositions, or portions thereof, which may be read into evidence and
`
`statements of any objections thereto, including:
`
`(1)
`
`Plaintiffs’ initial deposition designations, Defendants’ objections and
`
`counter-designations thereto, and Plaintiffs’ objections to Defendants’ counter-designations and
`
`reply designations (see Schedule F-1).
`
`(2)
`
`Defendants’ initial deposition designations, Plaintiffs’ objections and
`
`counter-designations thereto, and Defendants’ objections to Plaintiffs’ counter-designations and
`
`reply designations (see Schedule F-2).
`
`(3)
`
`To the extent admissible under the Federal Rules of Civil Procedure and
`
`Federal Rules of Evidence, a Party may introduce deposition testimony by videotape or by
`
`transcript. When deposition designation excerpts are introduced, all admissible deposition
`
`counter-designation excerpts, whether offered by videotape or by transcript, will be introduced
`
`simultaneously in the sequence in which the testimony was originally given. If an exhibit is
`
`referenced in a deposition designation, the exhibit is admitted into evidence if it is included on
`
`the offering party’s trial exhibit list and is not otherwise objected to.
`
`(4)
`
`To the extent such designations are read or played in open court, each
`
`Party will be charged for the time taken to read or play its designations and the opposing side
`
`will be charged for the time taken to read or play its counter-designations.
`
`
`
`7
`
`

`

`Case 1:14-cv-01171-GMS Document 259 Filed 09/15/16 Page 12 of 170 PageID #: 5543
`
`(5)
`
`A Party who wishes to enter deposition testimony into the record shall
`
`provide to the other Party at least 48 hours’ notice of the name of the witness and the specific
`
`excerpts that the Party intends to enter into the record. Transcripts of designated testimony will
`
`be submitted to the Court and the court reporter and made part of the trial record. Colloquy
`
`between counsel and objections will be eliminated when the deposition is read or viewed at trial.
`
`(6)
`
`Any deposition testimony not specifically identified on a Party’s
`
`deposition designation list still may be used at trial for the purpose of impeachment, if otherwise
`
`competent for such purposes.
`
`(7)
`
`The parties reserve the right to withdraw and/or narrow testimony that
`
`they have affirmatively designated in Schedules F-1 and F-2, but must provide 48 hours’ notice
`
`to the other party if they chose to do so, along with a copy of the revised deposition designations.
`
`The counter-designating party must provide any revisions within 24 hours of receipt. If
`
`applicable, a party’s designation of a page and line from a particular transcript shall be
`
`automatically deemed to include any errata indicated for that page and line in the attached errata
`
`sheets.
`
`g)
`
`Itemized statements of special damages are not applicable to this action.
`
`h) Waivers of any claims or defenses that have been abandoned by any party (see
`
`Schedule H-1 (Plaintiffs’ Waivers) and Schedule H-2 (Defendants’ Waivers)).
`
`i)
`
`The parties’ proposed Findings of Fact and Conclusions of Law in duplicate (see
`
`Schedule I-1 (Plaintiffs’ Proposed Findings of Fact and Conclusions of Law) and Schedule I-2
`
`(Defendants’ Proposed Findings of Fact and Conclusions of Law)).
`
`j)
`
`The parties have, in good faith, met and conferred regarding settlement and have
`
`been unable to agree to settlement terms.
`
`8
`
`
`
`

`

`Case 1:14-cv-01171-GMS Document 259 Filed 09/15/16 Page 13 of 170 PageID #: 5544
`
`k)
`
`Each party has completed discovery, including the depositions of expert
`
`witnesses. Absent good cause shown, no further discovery shall be permitted.
`
`l)
`
`No motions in limine will be filed. Lists of evidentiary issues the parties intend to
`
`raise (see Schedule L-1 (Plaintiffs’ List of Evidentiary Issues It Intends to Raise) and Schedule
`
`L-2 (Defendants’ List of Evidentiary Issues They Intend to Raise)). The parties shall be
`
`prepared to address their evidentiary issues at the Pretrial Conference and during trial (before and
`
`after the trial day).
`
`3.
`
`Trial of this case is expected to take seven days, beginning at 9:00 a.m. (ET) on
`
`September 26, 2016 through September 30, 2016. Trial will be adjourned October 3, 2016
`
`through October 4, 2016 for Rosh Hashanah. Trial will resume October 5, 2016 through October
`
`6, 2016.
`
`4.
`
`The parties agree that the time available for trial shall be split evenly between Plaintiffs,
`
`on the one hand, and Defendants, on the other, with opening statements, closing arguments (if
`
`any), and cross-examination counting toward a party’s time.
`
`5.
`
`6.
`
`This is a non-jury trial.
`
`This Order will control the course of the trial and may not be amended except by consent
`
`of the parties and the Court, or by order of the court to prevent manifest injustice.
`
`7.
`
`8.
`
`Possibility of settlement of this case was considered by the parties.
`
`The Court has entered a Stipulated Protective Order (Docket No. 14-cv-01171-GMS, D.I.
`
`66) to safeguard the confidentiality of certain of the Parties’ business and technical information,
`
`as well as that of third parties. Nonetheless, the presentation of evidence at trial shall take place
`
`in open court, unless a party specifically requests (for example (only), Sandoz and Momenta plan
`
`to make this request for any testimony and exhibits concerning the marketing, sales etc. of
`
`
`
`9
`
`

`

`Case 1:14-cv-01171-GMS Document 259 Filed 09/15/16 Page 14 of 170 PageID #: 5545
`
`Glatopa®), and the Court agrees, that the Court be closed to the public during presentation of
`
`certain portions of the evidence. The Parties have stipulated that each party may have up to 5
`
`corporate representatives attend any closed, confidential portions of the trial, subject to the terms
`
`and conditions of the Stipulated Protective Order.
`
`
`
`10
`
`

`

`Case 1:14-cv-01171-GMS Document 259 Filed 09/15/16 Page 15 of 170 PageID #: 5546
`
`/s/ Stephen B. Brauerman
`Richard D. Kirk (No. 922)
`Stephen B. Brauerman (No. 4952)
`Sara E. Bussiere (No. 5725)
`BAYARD, P.A.
`222 Delaware Avenue, Suite 900
`Wilmington, DE 19801
`(302) 655-5000
`rkirk@bayardlaw.com
`sbrauerman@bayardlaw.com
`sbussiere@bayardlaw.com
`
`
`/s/ Karen E. Keller
`John W. Shaw (No. 3362)
`Karen E. Keller (No. 4489)
`David M. Fry (No. 5486)
`SHAW KELLER LLP
`300 Delaware Avenue, Suite 1120
`Wilmington, DE 19801
`(302) 298-0700
`jshaw@shawkeller.com
`kkeller@shawkeller.com
`dfry@shawkeller.com
`
`David M. Hashmall
`Elizabeth J. Holland
`GOODWIN PROCTER LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018
`(212) 813-8800
`
`Paul F. Ware
`Daryl L. Wiesen
`John T. Bennett
`Nicholas K. Mitrokostas
`GOODWIN PROCTER LLP
`100 Northern Avenue
`Boston, MA 02110
`(617) 570-1000
`
`William G. James
`GOODWIN PROCTER LLP
`901 New York Avenue, NW
`Washington, DC 20001
`(202) 346-4000
`
`Attorneys for Plaintiffs
`
`
`
`
`
`11
`
`

`

`Case 1:14-cv-01171-GMS Document 259 Filed 09/15/16 Page 16 of 170 PageID #: 5547
`
`/s/ Richard L. Renck
`Richard L. Renck (No. 3893)
`DUANE MORRIS LLP
`222 Delaware Avenue, Suite 1600
`Wilmington, DE 19801
`(302) 657-4900
`rlrenck@duanemorris.com
`
`Anthony J. Fitzpatrick
`Vincent L. Capuano
`Christopher S. Kroon
`Carolyn A. Alenci
`DUANE MORRIS LLP
`100 High Street, Suite 2400
`Boston, MA 02110
`(857) 488-4200
`
`Attorneys for Amneal Pharmaceuticals LLC
`
`
`
`/s/ Frederick L. Cottrell, III
`Frederick L. Cottrell, III (No. 2555)
`Arun Mohan (No. 6110)
`RICHARDS, LAYTON & FINGER, P.C.
`One Rodney Square
`920 North King Street
`Wilmington, DE 19801
`(302) 651-7700
`cottrell@rlf.com
`mohan@rlf.com
`
`Shannon M. Bloodworth
`PERKINS COIE LLP
`700 13th Street, NW
`Washington, DC 20005
`(202) 654-6204
`
`Attorneys for Mylan Inc., Mylan
`Pharmaceuticals Inc. and Natco Pharma
`Ltd.
`
`
`
`/s/ John C. Phillips, Jr.
`John C. Phillips, Jr. (No. 110)
`David A. Bilson (No. 4986)
`PHILLIPS, GOLDMAN, MCLAUGHLIN
` & HALL, P.A.
`1200 North Broom Street
`Wilmington, DE 19806
`jcp@pgmhlaw.com
`dab@pgmhlaw.com
`
`Constance S. Huttner
`Beshoy M. Sharoupim
`BUDD LARNER, P.C.
`150 John F. Kennedy Parkway
`Short Hills, NJ 07078
`(973) 315-4430
`
`Attorneys for DRL Defendants
`
`
`
`
`/s/ Dominick T. Gattuso
`Dominick T. Gattuso (No. 3630)
`PROCTOR HEYMAN ENERIO LLP
`300 Delaware Avenue, Suite 200
`Wilmington, DE 19801
`(308) 472-7300
`dgattuso@proctorheyman.com
`
`William A. Rakoczy
`Deanne M. Mazzochi
`Rachel Pernic Waldron
`RAKOCZY MOLINO MAZZOCHI SIWIK LLP
`6 West Hubbard Street, Suite 500
`Chicago, IL 60654
`(312) 222-7543
`wrakoczy@rmmslegal.com
`dmazzochi@rmmslegal.com
`rwaldron@rmmslegal.com
`
`Attorneys for Defendants Sandoz Inc.
`and Momenta Pharmaceuticals, Inc.
`
`
`
`
`
`12
`
`

`

`Case 1:14-cv-01171-GMS Document 259 Filed 09/15/16 Page 17 of 170 PageID #: 5548
`
`
`
`/s/ Neal C. Belgam
`Neal C. Belgam (No. 2721)
`Eve H. Ormerod (No. 5369)
`SMITH, KATZENSTEIN & JENKINS LLP
`1000 West Street, Suite 1501
`P.O. Box 410
`Wilmington, DE 19899 (courier 19801)
`(302) 652-8400
`nbelgam@skjlaw.com
`eormerod@skjlaw.com
`
`E. Anthony Figg
`Sharon L. Davis
`R. Elizabeth Brenner-Leifer
`Seth E. Cockrum
`Jennifer Nock
`ROTHWELL, FIGG, ERNST &
`MANBECK, P.C.
`607 14th Street, NW, Suite 800
`Washington, DC 20005
`(202) 783-6040
`
`Attorneys for Synthon Pharmaceuticals Inc.,
`Synthon B.V, Synthon s.r.o., and Pfizer, Inc.
`
`
`
`IT IS SO ORDERED this ___ day of September 2016.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`The Honorable Gregory M. Sleet
`
`
`
`13
`
`

`

`Case 1:14-cv-01171-GMS Document 259 Filed 09/15/16 Page 18 of 170 PageID #: 5549
`
`
`CERTIFICATE OF SERVICE
`
`I, Karen E. Keller, hereby certify that on September 1, 2016, this document was served
`
`on the persons listed below in the manner indicated:
`
`BY FTP
`Neal C. Belgam
`SMITH KATZENSTEIN & JENKINS LLP
`1000 West Street, Suite 1501
`P.O. Box 410
`Wilmington, DE 19899
`nbelgam@skjlaw.com
`Attorney for Defendants Synthon
`Pharmaceuticals Inc., Synthon B.V.,
`and Synthon S.R.O. Blansko
`
`
`Richard L. Renck
`DUANE MORRIS LLP
`222 Delaware Avenue, Suite 1600
`Wilmington, DE 19801
`rlrenck@duanemorris.com
`Attorneys for Amneal
`Pharmaceuticals LLC
`
`
`E. Anthony Figg
`Sharon L. Davis
`R. Elizabeth Brenner-Leifer
`Seth E. Cockrum Ph.D.
`Jennifer P. Nock
`ROTHWELL, FIGG, ERNST & MANBECK P.C.
`607 14th Street, NW, Suite 800
`Washington, D.C. 20005
`efigg@rfem.com
`sdavis@rfem.com
`ebrenner@rfem.com
`scockrum@rfem.com
`jnock@rfem.com
`
`Vincent L. Capuano, Ph.D.
`Anthony J. Fitzpatrick
`Carolyn A. Alenci
`Christopher S. Koon
`DUANE MORRIS LLP
`100 High Street, Suite 2400
`Boston, MA 02110
`vcapuano@duanemorris.com
`ajfitzpatrick@duanemorris.com
`caalenci@duanemorris.com
`ckoon@duanemorris.com
`
`Patrick C. Gallagher, Ph.D.
`DUANE MORRIS LLP
`190 South LaSalle Street, Suite 3700
`Chicago, IL 60603
`pcgallagher@duanemorris.com
`
`
`
`
`

`

`Case 1:14-cv-01171-GMS Document 259 Filed 09/15/16 Page 19 of 170 PageID #: 5550
`
`Frederick L. Cottrell, III
`RICHARDS, LAYTON & FINGER, P.A.
`One Rodney Square
`920 N. King Street
`Wilmington, DE 19801
`cottrell@rlf.com
`Attorneys for Mylan Pharmaceuticals
`Inc. and Mylan Inc.
`
`John C. Phillips, Jr.
`David A. Bilson
`PHILLIPS, GOLDMAN & SPENCE, P.A.
`1200 North Broom Street
`Wilmington, DE 19806
`jcp@pgslaw.com
`dab@pgslaw.com
`Attorneys for Doctor Reddy’s
`Laboratories, Ltd. and Doctor
`Reddy’s Laboratories, Inc.
`
`
`Shannon M. Bloodworth
`David L. Anstaett
`Crystal R. Canterbury
`Robert D. Swanson
`Brandon M. White
`PERKINS COIE LLP
`700 13th Street, NW, Suite 600
`Washington, D.C. 20005
`sbloodworth@perkinscoie.com
`danstaett@perkinscoie.com
`ccanterbury@perkinscoie.com
`rswanson@perkinscoie.com
`bmwhite@perkinscoie.com
`
`Emily J. Greb
`PERKINS COIE LLP
`1 East Main Street, Suite 201
`Madison, WI 53703
`egrab@perkinscoie.com
`
`Constance Huttner
`Alfred Henry Heckel
`BUDD LARNER P.C.
`150 John F. Kennedy Parkway
`Short Hills, NJ 07078
`chuttner@buddlarner.com
`hheckel@buddlarner.com
`
`2
`
`

`

`Case 1:14-cv-01171-GMS Document 259 Filed 09/15/16 Page 20 of 170 PageID #: 5551
`
`Dominick T. Gattuso
`PROCTOR HEYMAN ENERIO LLP
`300 Delaware Avenue, Suite 200
`Wilmington, DE 19801
`dgattuso@proctorheyman.com
`Attorneys for Sandoz Inc. and
`Momenta Pharmaceuticals Inc.
`
`
`William A. Rakoczy
`Deanne M. Mazzochi
`Rachel Pernic Waldron
`Christopher P. Galligan
`Erin M. Forbes
`Matthew V. Anderson
`Thomas H. Ehrich
`RAKOCZY MOLINO MAZZOCHI SIWIK LLP
`6 West Hubbard Street, Suite 500
`Chicago, IL 60654
`wrakoczy@rmmslegal.com
`dmazzochi@rmmslegal.com
`rwaldron@rmmslegal.com
`cgalligan@rmmslegal.com
`eforbes@rmmslegal.com
`manderson@rmmslegal.com
`tehrich@rmmslegal.com
`
`
`
`
`
`
`/s/ Karen E. Keller
`John W. Shaw (No. 3362)
`Karen E. Keller (No. 4489)
`David M. Fry (No. 5486)
`SHAW KELLER LLP
`300 Delaware Avenue, Suite 1120
`Wilmington, DE 19801
`(302) 298-0700
`jshaw@shawkeller.com
`kkeller@shawkeller.com
`dfry@shawkeller.com
`Attorneys for Plaintiffs Teva Pharmaceuticals
`USA, Inc., Teva Pharmaceutical Industries,
`Ltd., Teva Neuroscience, Inc. and Yeda
`Research and Development Co., Ltd.
`(C.A. Nos. 14-1172, 14-1278 and 14-1419)
`
`
`
`
`
`
`3
`
`

`

`Case 1:14-cv-01171-GMS Document 259 Filed 09/15/16 Page 21 of 170 PageID #: 5552
`
`SCHEDULE A
`STATEMENT OF ALL UNCONTESTED FACTS
`
`I.
`
`Parties
`
`A.
`
`1.
`
`Teva
`
`Teva Pharmaceuticals USA, Inc. (“Teva USA”) is a Delaware corporation with its
`
`principal place of business at 1090 Horsham Road, North Wales, Pennsylvania 19454-1090.
`
`2.
`
`Teva Pharmaceutical Industries Ltd. (“Teva Ltd.”) is an Israeli company with its
`
`principal place of business at 5 Basel Street, P.O. Box 3190, Petah Tikva, 49131, Israel.
`
`3.
`
`Teva Neuroscience, Inc. (“Teva Neuroscience”), is a Delaware corporation with
`
`its principal place of business at 901 E. 104th Street, Suite 900, Kansas City, Missouri 64131.
`
`4.
`
`Yeda Research and Development Co. Ltd. (“Yeda”) is an Israeli company with its
`
`principal place of business at P.O. Box 95, Rehovot, 76100, Israel.
`
`B.
`
`5.
`
`Amneal
`
`Amneal Pharmaceuticals LLC is a limited liability company organized and
`
`existing under the laws of Delaware with a principal place of business at 400 Crossing Blvd.,
`
`Third Floor, Bridgewater, NJ 08807-2863.
`
`6.
`
`Amneal GmbH is a limited liability company organized and existing under the
`
`laws of Switzerland with a principal place of business at Turnstrasse 30, 6312 Steinhausen –
`
`Switzerland.
`
`C.
`
`7.
`
`DRL
`
`Doctor Reddy’s Laboratories Ltd. is a corporation organized and existing under
`
`the laws of India with its principal place of business at 8-2-337, Road No. 3, Banjara Hills,
`
`Hyderabad, Telangana 500 034, India.
`
` A-1
`
`

`

`Case 1:14-cv-01171-GMS Document 259 Filed 09/15/16 Page 22 of 170 PageID #: 5553
`
`8.
`
`Doctor Reddy’s Laboratories Inc. is a corporation organized and existing under
`
`the laws of New Jersey with its principal place of business at 107 College Road East, Princeton,
`
`NJ 08540, and is a wholly-owned subsidiary of Doctor Reddy’s Laboratories Ltd.
`
`D. Mylan
`
`9.
`
`Mylan Pharmaceuticals Inc. is a corporation organized and existing under the
`
`laws of West Virginia with its principal place of business at 781 Chestnut Ridge Rd.,
`
`Morgantown, WV 26505.
`
`10. Mylan Pharmaceuticals Inc. is a wholly-owned subsidiary of Mylan Inc.
`
`11. Mylan Inc. is a corporation organized and existing under the laws of Pennsylvania
`
`with its principal place of business at 1000 Mylan Blvd., Canonsburg, PA 15317.
`
`E.
`
`12.
`
`Sandoz
`
`Sandoz Inc. is a corporation organized and existing under the laws of Colorado
`
`with its principal place of business at 100 College Road West, Princeton, NJ 08540.
`
`13. Momenta Pharmaceuticals, Inc. is a corporation organized and existing under the
`
`laws of Delaware with its principal place of business at 675 West Kendall Street, C